Fox Run Management, L.L.C. Biogen Inc. Transaction History

Fox Run Management, L.L.C.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$212.02 - $267.71 $418,527 - $528,459	1,974 New	1,974 $425,000
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $655,095 - $756,982	2,380 New	2,380 $677,000
Q4 2022 Feb 07, 2023	BUY	$252.44 - $306.72 $468,023 - $568,658	1,854 New	1,854 $513,000
Q2 2022 Aug 12, 2022	BUY	$187.54 - $223.02 $235,362 - $279,890	1,255 Added 78.1%	2,862 $584,000
Q1 2022 May 10, 2022	BUY	$193.77 - $244.14 $311,388 - $392,332	1,607 New	1,607 $338,000
Q4 2021 Feb 09, 2022	SELL	$223.92 - $287.77 $158,311 - $203,453	-707 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $200,073 - $260,918	707 New	707 $200,000
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $526,823 - $727,943	-2,394 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$217.44 - $243.88 $44,140 - $49,507	203 Added 9.27%	2,394 $557,000
Q2 2019 Jul 17, 2019	SELL	$219.29 - $241.72 $17,323 - $19,095	-79 Reduced 3.48%	2,191 $512,000
Q1 2019 Oct 17, 2019	BUY	$216.71 - $338.96 $217,793 - $340,654	1,005 Added 79.45%	2,270 $537,000
Q4 2018 Jan 15, 2019	BUY	$278.5 - $352.75 $352,302 - $446,228	1,265 New	1,265 $381,000

1,050

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $29.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.